Risk of proteinuria with atezolizumab plus bevacizumab versus lenvatinib in first-line systemic treatment for hepatocellular carcinoma.

被引：0
|
作者：
Yang, JIwon
Choi, Won-Mook
Kim, Hyung-Don
Choi, Jonggi
Yoo, Changhoon
Lee, Danbi
Shim, Ju Hyun
Kim, Kang Mo
Lim, Young-Suk
Lee, Han Chu
机构：
[1] Univ Ulsan, Liver Ctr, Asan Med Ctr, Dept Gastroenterol,Coll Med, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[4] Univ Ulsan, Liver Ctr, Asan Med Ctr, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.558
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：558 / 558
页数：1
相关论文
共 50 条
  • [31] Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Chen, Xiaoyu
    CANCER, 2022, 128 (22) : 3995 - 4003
  • [32] Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
    Niizeki, Takashi
    Tokunaga, Takayuki
    Takami, Yuko
    Wada, Yoshiyuki
    Harada, Masaru
    Shibata, Michihiko
    Nakao, Kazuhiko
    Sasaki, Ryu
    Hirai, Fumihito
    Shakado, Satoshi
    Yoshizumi, Tomoharu
    Itoh, Shinji
    Yatsuhashi, Hiroshi
    Bekki, Shigemune
    Ido, Akio
    Mawatari, Seiichi
    Honda, Koichi
    Sugimoto, Rie
    Senju, Takeshi
    Takahashi, Hirokazu
    Kuwashiro, Takuya
    Maeshiro, Tatsuji
    Nakamuta, Makoto
    Aratake, Yoshifusa
    Yamashita, Tsutomu
    Otsuka, Yuichiro
    Matsumoto, Shuichi
    Sohda, Tetsuro
    Shimose, Shigeo
    Murotani, Kenta
    Tanaka, Yasuhito
    TARGETED ONCOLOGY, 2022, 17 (06) : 643 - 653
  • [33] Response to letter entitled Re: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
    Persano, Mara
    Rimini, Margherita
    Gardini, Andrea Casadei
    EUROPEAN JOURNAL OF CANCER, 2023, 192
  • [34] Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
    Takashi Niizeki
    Takayuki Tokunaga
    Yuko Takami
    Yoshiyuki Wada
    Masaru Harada
    Michihiko Shibata
    Kazuhiko Nakao
    Ryu Sasaki
    Fumihito Hirai
    Satoshi Shakado
    Tomoharu Yoshizumi
    Shinji Itoh
    Hiroshi Yatsuhashi
    Shigemune Bekki
    Akio Ido
    Seiichi Mawatari
    Koichi Honda
    Rie Sugimoto
    Takeshi Senju
    Hirokazu Takahashi
    Takuya Kuwashiro
    Tatsuji Maeshiro
    Makoto Nakamuta
    Yoshifusa Aratake
    Tsutomu Yamashita
    Yuichiro Otsuka
    Shuichi Matsumoto
    Tetsuro Sohda
    Shigeo Shimose
    Kenta Murotani
    Yasuhito Tanaka
    Targeted Oncology, 2022, 17 : 643 - 653
  • [35] Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
    Su, Dan
    Wu, Bin
    Shi, Lizheng
    JAMA NETWORK OPEN, 2021, 4 (02)
  • [36] Combined atezolizumab and bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma: A single center experience
    Khalil, A. A.
    Abdelaziz, M. A.
    El Nahas, T. I.
    ANNALS OF ONCOLOGY, 2024, 35 : S1492 - S1493
  • [37] CLINICAL USEFULNESS OF LENVATINIB AS SECOND- LINE TREATMENT FOR HEPATOCELLULAR CARCINOMA FOLLOWING ATEZOLIZUMAB PLUS BEVACIZUMAB FAILURE
    Hiraoka, Atsushi
    Tada, Toshifumi
    Hirooka, Masashi
    Kariyama, Kazuya
    Itobayashi, Ei
    Kunihiko, Tsuji
    Ishikawa, Toru
    Toyoda, Hidenori
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Naganuma, Atsushi
    Matono, Tomomitsu
    Ohama, Hideko
    Tada, Fujimasa
    Nouso, Kazuhiro
    Hiasa, Yoichi
    Kumada, Takashi
    HEPATOLOGY, 2023, 78 : S1816 - S1817
  • [38] Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries
    Lee, Choong-kun
    Yoo, Changhoon
    Hong, Jung Yong
    Park, Se Jun
    Kim, Jin Won
    Tai, David Wai Meng
    Kim, Hyeyeong
    Korphaisarn, Krittiya
    Tanasanvimon, Suebpong
    Chen, San-Chi
    Kim, Ju Won
    Kim, Ilhwan
    Kim, Moonho
    Choo, Joan
    Oh, Sang-Bo
    Chen, Ching-Tso
    Bae, Woo Kyun
    Kim, Hongsik
    Huh, Seok Jae
    Yen, Chia-Jui
    Park, Sejung
    Lee, Dong Ki
    Chan, Landon Long
    Kang, Beodeul
    Kang, Minsu
    Sundar, Raghav
    Choi, Hye Jin
    Chan, Stephen Lam
    Chon, Hong Jae
    Lee, Myung-Ah
    LIVER CANCER, 2024,
  • [39] Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
    Yano, Shigeki
    Kawaoka, Tomokazu
    Johira, Yusuke
    Miura, Ryoichi
    Kosaka, Masanari
    Shirane, Yuki
    Murakami, Serami
    Amioka, Kei
    Naruto, Kensuke
    Ando, Yuwa
    Kosaka, Yumi
    Yamaoka, Kenji
    Kodama, Kenichiro
    Uchikawa, Shinsuke
    Fujino, Hatsue
    Ohno, Atsushi
    Nakahara, Takashi
    Murakami, Eisuke
    Okamoto, Wataru
    Yamauchi, Masami
    Imamura, Michio
    Mori, Keiichi
    Arihiro, Kouji
    Kuroda, Shintaro
    Kobayashi, Tsuyoshi
    Ohdan, Hideki
    Aikata, Hiroshi
    MEDICINE, 2021, 100 (42) : E27576
  • [40] Importance of Atezolizumab Plus Bevacizumab Combination Treatment as First-line Therapy for Immunological Changes in Patients With Unresectable Hepatocellular Carcinoma
    Kobayashi, Kojiro
    Nagai, Hidenari
    Matsui, Teppei
    Matsuda, Takahisa
    Higai, Koji
    ANTICANCER RESEARCH, 2023, 43 (10) : 4601 - 4609
12345